John Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $4.64, for a total value of $13,920.00. Following the transaction, the director now directly owns 141,950 shares in the company, valued at approximately $658,648. This trade represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Joseph Johnston also recently made the following trade(s):

  • On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.01, for a total value of $12,030.00.

MaxCyte Trading Down 0.9 %

NASDAQ MXCT opened at $4.64 on Thursday. The company has a market cap of $490.49 million, a P/E ratio of -13.65 and a beta of 1.29. The company has a fifty day simple moving average of $4.20 and a 200 day simple moving average of $4.08. MaxCyte, Inc. has a 12-month low of $3.16 and a 12-month high of $5.29.




MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $8.16 million during the quarter, compared to analysts' expectations of $7.50 million. During the same period last year, the company earned ($0.11) earnings per share. Sell-side analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC bought a new stake in MaxCyte during the third quarter worth $51,000. China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company's stock worth $79,000 after acquiring an additional 7,930 shares during the last quarter. Verition Fund Management LLC grew its stake in shares of MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock worth $83,000 after acquiring an additional 6,045 shares in the last quarter. Creative Planning raised its holdings in shares of MaxCyte by 33.6% in the third quarter. Creative Planning now owns 28,652 shares of the company's stock valued at $111,000 after purchasing an additional 7,212 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of MaxCyte by 84.5% during the third quarter. SG Americas Securities LLC now owns 37,969 shares of the company's stock valued at $148,000 after purchasing an additional 17,385 shares in the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

About MaxCyte

(Get Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Read More

Insider Buying and Selling by Quarter for MaxCyte (NASDAQ:MXCT)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at MaxCyte?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for MaxCyte and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles